Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 8
2004 2
2005 5
2006 4
2007 3
2008 5
2009 8
2010 7
2011 5
2012 13
2013 8
2014 11
2015 11
2016 16
2017 13
2018 11
2019 14
2020 11
2021 20
2022 15
2023 16
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Magrin E, Semeraro M, Hebert N, Joseph L, Magnani A, Chalumeau A, Gabrion A, Roudaut C, Marouene J, Lefrere F, Diana JS, Denis A, Neven B, Funck-Brentano I, Negre O, Renolleau S, Brousse V, Kiger L, Touzot F, Poirot C, Bourget P, El Nemer W, Blanche S, Tréluyer JM, Asmal M, Walls C, Beuzard Y, Schmidt M, Hacein-Bey-Abina S, Asnafi V, Guichard I, Poirée M, Monpoux F, Touraine P, Brouzes C, de Montalembert M, Payen E, Six E, Ribeil JA, Miccio A, Bartolucci P, Leboulch P, Cavazzana M. Magrin E, et al. Among authors: asnafi v. Nat Med. 2022 Jan;28(1):81-88. doi: 10.1038/s41591-021-01650-w. Epub 2022 Jan 24. Nat Med. 2022. PMID: 35075288 Clinical Trial.
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL). Huguet F, et al. Among authors: asnafi v. J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29863974 Free article. Clinical Trial.
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.
van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). van Dongen JJ, et al. Among authors: asnafi v. Leukemia. 2012 Sep;26(9):1908-75. doi: 10.1038/leu.2012.120. Epub 2012 May 3. Leukemia. 2012. PMID: 22552007 Free PMC article.
HiJAKing T-ALL.
Asnafi V. Asnafi V. Blood. 2014 Nov 13;124(20):3038-40. doi: 10.1182/blood-2014-09-600627. Blood. 2014. PMID: 25395141 Free article.
[Immunopathology of the small intestine].
Bruneau J, Khater S, Isnard P, Lhermitte L, Brouzes C, Sibon D, Asnafi V, Berrebi D, Rabant M, Neven B, Cellier C, Hermine O, Molina TJ. Bruneau J, et al. Among authors: asnafi v. Ann Pathol. 2023 Jun;43(3):252-265. doi: 10.1016/j.annpat.2023.03.004. Epub 2023 May 6. Ann Pathol. 2023. PMID: 37156715 Review. French.
IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.
Courtois L, Cabannes-Hamy A, Kim R, Delecourt M, Pinton A, Charbonnier G, Feroul M, Smith C, Tueur G, Pivert C, Balducci E, Simonin M, Angel LH, Spicuglia S, Boissel N, Andrieu GP, Asnafi V, Rousselot P, Lhermitte L. Courtois L, et al. Among authors: asnafi v. Blood. 2023 Jul 13;142(2):158-171. doi: 10.1182/blood.2022017948. Blood. 2023. PMID: 37023368
PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption.
Ladraa S, Zerbib L, Bayard C, Fraissenon A, Venot Q, Morin G, Garneau AP, Isnard P, Chapelle C, Hoguin C, Fraitag S, Duong JP, Guibaud L, Besançon A, Kaltenbach S, Villarese P, Asnafi V, Broissand C, Goudin N, Dussiot M, Nemazanyy I, Viel T, Autret G, Cruciani-Guglielmacci C, Denom J, Bruneau J, Tavitian B, Legendre C, Dairou J, Lacorte JM, Levy P, Pende M, Polak M, Canaud G. Ladraa S, et al. Among authors: asnafi v. Sci Adv. 2022 Dec 9;8(49):eade7823. doi: 10.1126/sciadv.ade7823. Epub 2022 Dec 9. Sci Adv. 2022. PMID: 36490341 Free PMC article.
RUNX1 as a recombinase cofactor.
Cieslak A, Payet-Bornet D, Asnafi V. Cieslak A, et al. Among authors: asnafi v. Oncotarget. 2015 Sep 8;6(26):21793-4. doi: 10.18632/oncotarget.5488. Oncotarget. 2015. PMID: 26393399 Free PMC article. No abstract available.
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Among authors: asnafi v. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.
Balducci E, Steimlé T, Smith C, Villarese P, Feroul M, Payet-Bornet D, Kaltenbach S, Couronné L, Lhermitte L, Touzart A, Dourthe ME, Simonin M, Baruchel A, Dombret H, Ifrah N, Boissel N, Nadel B, Macintyre E, Cieslak A, Asnafi V. Balducci E, et al. Among authors: asnafi v. Mol Cancer. 2023 Jul 10;22(1):108. doi: 10.1186/s12943-023-01794-y. Mol Cancer. 2023. PMID: 37430263 Free PMC article.
177 results